Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

Kimberly L. Blackwell, Harold J. Burstein, Anna Maria Storniolo, Hope Rugo, George Sledge, Maria Koehler, Catherine Ellis, Michelle Casey, Svetislava Vukelja, Joachim Bischoff, Jose Baselga, Joyce O'Shaughnessy

Research output: Contribution to journalArticle

613 Citations (Scopus)

Abstract

Purpose: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients and Methods: Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either lapatinib alone or in combination with trastuzumab. The primary end point was progression-free survival (PFS). Secondary efficacy end points included overall response rate (ORR), clinical benefit rate (CBR; complete response, partial response, and stable disease for ≥ 24 weeks), and overall survival (OS). Results: In the intent-to-treat population (N = 296) who received a median of three prior trastuzumabcontaining regimens, the combination of lapatinib with trastuzumab was superior to lapatinib alone for PFS (hazard ratio [HR] = 0.73; 95% CI, 0.57 to 0.93; P = .008) and CBR (24.7% in the combination arm v 12.4% in the monotherapy arm; P = .01). A trend for improved OS in the combination arm was observed (HR = 0.75; 95% CI, 0.53 to 1.07; P = .106). There was no difference in ORR (10.3% in the combination arm v 6.9% in the monotherapy arm; P = .46). The most frequent adverse events were diarrhea, rash, nausea, and fatigue; diarrhea was higher in the combination arm (P = .03). The incidence of symptomatic and asymptomatic cardiac events was low (combination therapy = 2% and 3.4%; monotherapy = 0.7% and 1.4%, respectively). Conclusion: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.

Original languageEnglish
Pages (from-to)1124-1130
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number7
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Breast Neoplasms
Disease-Free Survival
Diarrhea
Survival
Trastuzumab
lapatinib
Exanthema
Nausea
Fatigue
Disease Progression
Safety
Drug Therapy
Cell Line
Incidence
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. / Blackwell, Kimberly L.; Burstein, Harold J.; Storniolo, Anna Maria; Rugo, Hope; Sledge, George; Koehler, Maria; Ellis, Catherine; Casey, Michelle; Vukelja, Svetislava; Bischoff, Joachim; Baselga, Jose; O'Shaughnessy, Joyce.

In: Journal of Clinical Oncology, Vol. 28, No. 7, 01.03.2010, p. 1124-1130.

Research output: Contribution to journalArticle

Blackwell, KL, Burstein, HJ, Storniolo, AM, Rugo, H, Sledge, G, Koehler, M, Ellis, C, Casey, M, Vukelja, S, Bischoff, J, Baselga, J & O'Shaughnessy, J 2010, 'Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer', Journal of Clinical Oncology, vol. 28, no. 7, pp. 1124-1130. https://doi.org/10.1200/JCO.2008.21.4437
Blackwell, Kimberly L. ; Burstein, Harold J. ; Storniolo, Anna Maria ; Rugo, Hope ; Sledge, George ; Koehler, Maria ; Ellis, Catherine ; Casey, Michelle ; Vukelja, Svetislava ; Bischoff, Joachim ; Baselga, Jose ; O'Shaughnessy, Joyce. / Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 7. pp. 1124-1130.
@article{2b83156f09844b6b8e848fea07d283c7,
title = "Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer",
abstract = "Purpose: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients and Methods: Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either lapatinib alone or in combination with trastuzumab. The primary end point was progression-free survival (PFS). Secondary efficacy end points included overall response rate (ORR), clinical benefit rate (CBR; complete response, partial response, and stable disease for ≥ 24 weeks), and overall survival (OS). Results: In the intent-to-treat population (N = 296) who received a median of three prior trastuzumabcontaining regimens, the combination of lapatinib with trastuzumab was superior to lapatinib alone for PFS (hazard ratio [HR] = 0.73; 95{\%} CI, 0.57 to 0.93; P = .008) and CBR (24.7{\%} in the combination arm v 12.4{\%} in the monotherapy arm; P = .01). A trend for improved OS in the combination arm was observed (HR = 0.75; 95{\%} CI, 0.53 to 1.07; P = .106). There was no difference in ORR (10.3{\%} in the combination arm v 6.9{\%} in the monotherapy arm; P = .46). The most frequent adverse events were diarrhea, rash, nausea, and fatigue; diarrhea was higher in the combination arm (P = .03). The incidence of symptomatic and asymptomatic cardiac events was low (combination therapy = 2{\%} and 3.4{\%}; monotherapy = 0.7{\%} and 1.4{\%}, respectively). Conclusion: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.",
author = "Blackwell, {Kimberly L.} and Burstein, {Harold J.} and Storniolo, {Anna Maria} and Hope Rugo and George Sledge and Maria Koehler and Catherine Ellis and Michelle Casey and Svetislava Vukelja and Joachim Bischoff and Jose Baselga and Joyce O'Shaughnessy",
year = "2010",
month = "3",
day = "1",
doi = "10.1200/JCO.2008.21.4437",
language = "English",
volume = "28",
pages = "1124--1130",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

AU - Blackwell, Kimberly L.

AU - Burstein, Harold J.

AU - Storniolo, Anna Maria

AU - Rugo, Hope

AU - Sledge, George

AU - Koehler, Maria

AU - Ellis, Catherine

AU - Casey, Michelle

AU - Vukelja, Svetislava

AU - Bischoff, Joachim

AU - Baselga, Jose

AU - O'Shaughnessy, Joyce

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Purpose: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients and Methods: Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either lapatinib alone or in combination with trastuzumab. The primary end point was progression-free survival (PFS). Secondary efficacy end points included overall response rate (ORR), clinical benefit rate (CBR; complete response, partial response, and stable disease for ≥ 24 weeks), and overall survival (OS). Results: In the intent-to-treat population (N = 296) who received a median of three prior trastuzumabcontaining regimens, the combination of lapatinib with trastuzumab was superior to lapatinib alone for PFS (hazard ratio [HR] = 0.73; 95% CI, 0.57 to 0.93; P = .008) and CBR (24.7% in the combination arm v 12.4% in the monotherapy arm; P = .01). A trend for improved OS in the combination arm was observed (HR = 0.75; 95% CI, 0.53 to 1.07; P = .106). There was no difference in ORR (10.3% in the combination arm v 6.9% in the monotherapy arm; P = .46). The most frequent adverse events were diarrhea, rash, nausea, and fatigue; diarrhea was higher in the combination arm (P = .03). The incidence of symptomatic and asymptomatic cardiac events was low (combination therapy = 2% and 3.4%; monotherapy = 0.7% and 1.4%, respectively). Conclusion: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.

AB - Purpose: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients and Methods: Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either lapatinib alone or in combination with trastuzumab. The primary end point was progression-free survival (PFS). Secondary efficacy end points included overall response rate (ORR), clinical benefit rate (CBR; complete response, partial response, and stable disease for ≥ 24 weeks), and overall survival (OS). Results: In the intent-to-treat population (N = 296) who received a median of three prior trastuzumabcontaining regimens, the combination of lapatinib with trastuzumab was superior to lapatinib alone for PFS (hazard ratio [HR] = 0.73; 95% CI, 0.57 to 0.93; P = .008) and CBR (24.7% in the combination arm v 12.4% in the monotherapy arm; P = .01). A trend for improved OS in the combination arm was observed (HR = 0.75; 95% CI, 0.53 to 1.07; P = .106). There was no difference in ORR (10.3% in the combination arm v 6.9% in the monotherapy arm; P = .46). The most frequent adverse events were diarrhea, rash, nausea, and fatigue; diarrhea was higher in the combination arm (P = .03). The incidence of symptomatic and asymptomatic cardiac events was low (combination therapy = 2% and 3.4%; monotherapy = 0.7% and 1.4%, respectively). Conclusion: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.

UR - http://www.scopus.com/inward/record.url?scp=77949884661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949884661&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.21.4437

DO - 10.1200/JCO.2008.21.4437

M3 - Article

VL - 28

SP - 1124

EP - 1130

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -